Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $14.83 Consensus Target Price from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $16.7143.

KPTI has been the subject of a number of research analyst reports. The Goldman Sachs Group set a $12.00 price target on Karyopharm Therapeutics in a research report on Wednesday, December 17th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. Finally, Rodman & Renshaw started coverage on Karyopharm Therapeutics in a research note on Monday. They set a “buy” rating and a $28.00 target price on the stock.

Institutional Trading of Karyopharm Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jump Financial LLC bought a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at approximately $396,000. ADAR1 Capital Management LLC increased its stake in shares of Karyopharm Therapeutics by 100.0% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,000 shares of the company’s stock worth $368,000 after purchasing an additional 25,000 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $307,000. Bridgeway Capital Management LLC purchased a new position in Karyopharm Therapeutics in the second quarter valued at approximately $163,000. Finally, Persistent Asset Partners Ltd purchased a new position in Karyopharm Therapeutics in the fourth quarter valued at approximately $135,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $7.85 on Monday. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $10.99. The firm’s 50-day simple moving average is $7.86 and its 200 day simple moving average is $6.83. The stock has a market cap of $143.97 million, a PE ratio of -0.47 and a beta of 0.13.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million. As a group, analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.